← Eichor
Study identifier: NCT07021495 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

Condition: Chronic Spontaneous Urticaria (CSU) · Hidradenitis Suppurativa (HS) · Psoriasis (PsO)  ·  Sponsor: Leiden University Medical Center

PhaseN/A
Planned participants840
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers. This study is part of the larger NGID (Next Generation ImmunoDermatology) initiative, of which the main objective is to develop infrastructure that enables personalised patient care. The main questions the SKINERGY study aims to answer are: * Which biomarkers can discriminate between responders and non-responders to treatment in patients with AD, CLE, CSU, HS, MF, and PSO? * How do disease-related biomarkers in patients with AD, CLE, CSU, HS, MF, and PSO differ from those in healthy volunteers? * Which (multi-omics) biomarkers are associated with disease subtypes and predict response or non-response to (targeted) therapies in daily clinical practice? * How do biomarker profiles compare across different cohorts of patients with immune-mediated inflammatory skin diseases (AD, CLE, CSU, HS, MF, PSO) * How do biomarker levels change over time in response to treatment in these patient populations? * Which skin tissue biomarkers are associated with disease progression or treatment response? * How do the genomic profiles of patients differ across diseases or correlate with treatm…

This description comes directly from the study's public registry record.

Talk to the study team

Robert Rissmann, Professor  ·  +31 71 526 9111  ·  r.rissmann@lumc.nl

Martijn van Doorn, MD, PhD  ·  +31 10 704 0704  ·  m.b.a.vandoorn@erasmusmc.nl

Always discuss trial participation with your own doctor first.

Locations (8)

Radboud University Medical CenterNijmegen, Gelderland, NetherlandsNot Yet Recruiting
Maastricht University Medical Center+Maastricht, Limburg, NetherlandsNot Yet Recruiting
Amsterdam University Medical CenterAmsterdam, North Holland, NetherlandsNot Yet Recruiting
University Medical Center GroningenGroningen, Provincie Groningen, NetherlandsNot Yet Recruiting
Leiden University Medical CenterLeiden, South Holland, NetherlandsNot Yet Recruiting
Centre for Human Drug ResearchLeiden, South Holland, NetherlandsNot Yet Recruiting
Erasmus Medical CenterRotterdam, South Holland, NetherlandsNot Yet Recruiting
University Medical Center UtrechtUtrecht, Utrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07021495